Replies to post #401877 on Anavex Life Sciences Corp (AVXL)

[meds4life]

TGD is in a rush when answering. He needs to chill before doing these CC's. Answering at such a speed, "finishing" in as few seconds as possible - does not allow his own mind time to come up with related information to share - which may not be directly answering the query, but which would elaborate and give a wider, deeper view of the topic's answer.

But one has to want to do that in the first place[/I]

[Doc328]

Only problem with your "logic" lol is that the numbers were increased from 69 to 84 in September 2021 (before Avatar release) and then twice at CC's last year he talked up the virtue of AUC and even decisively stated it would be the endpoint in May 2022. Far more likely is that Dr. Jin advised them to stick to the original FDA-approved endpoints for Rett. Similar to the law, precedence plays a role.

Yun Zhong -- BTIG -- Analyst

So the-well, with regard to the primary endpoint is still going to be RSBQ AUC instead of -- RSBQ?

Christopher Missling -- President and Chief Executive Officer

-- Right. That's right. So when we presented AVATAR study, we learned from the first Phase 2 study that the RSBQ AUC that includes the CGI-I linked responder analysis. So the RSBQ AUC includes the CGI-I respond analysis linked to response analysis.

That is the endpoint, which we will also propose for the EXCELLENCE study. That is correct. It's consistent with the AVATAR study.

[Investor2014]

Nor did the AVATAR endpoint ever officially, as in on clinicaltrials.gov.

Well, as far as we can tell, the EXCELLENCE trial's endpoints have never officially changed from the beginning of the trial through to its recent conclusion.

Missling changed the readout to use AUC instead of the protocol EOT because it looked better, but blamed the CRO for being tardy with the clinicaltrials.gov updates.

I am disappointed with the lack of objective due diligence here.